At Sanofi, we have a rich history of MS research and treatment dating back to the 1970s. Through our partnership with Cambridge University, we have been at the forefront of delivering breakthrough medications to patients. Our commitment to patients and our passion for innovation in neurological disorders, such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and others, remains a top priority and investment for us.
We are driven by the desire to understand the science behind diseases like MS, which motivates us to challenge our assumptions and offer innovative solutions to meet the unmet needs of people affected by these conditions. With ongoing research into various treatments, we invite healthcare professionals to stay tuned for further updates and information later this year!

Thank you for visiting our Neurology page, and we look forward to your continued engagement and collaboration in advancing patient care.

MULTIPLE-SCLEROSIS

NEUROLOGY

Multiple Sclerosis

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

<h3>MAGE: patient satisfaction</h3>
MAGE was a real-world study investigating patient satisfaction in patients with T2D receiving&nbsp;Toujeo®.
There was an improvement of at least 2 points in DTSQ score at Month 6 from baseline, meeting the primary endpoint of the study.2
MAGE was a 6-month, multicentre, prospective, single-arm, observational, real-world study (conducted in Belgium) following 87 people with T2D who had been receiving basal and mealtime insulin for&nbsp;≥6 months.
Primary endpoint: change in DTSQ total score (baseline to Month 6).2
DTSQ: Diabetes Treatment Satisfaction Questionnaire.

Safety Profile

Abbreviations

References

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

Lantus® (insulin glargine 100 units/mL) Prescribing Information GB

Lantus® (insulin glargine 100 units/mL) Prescribing Information NI

Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

TYPE-2-DIABETES

DIABETES

Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D

<h3>Treatment persistence3</h3>
Toujeo® (insulin glargine 300 Units/mL) was associated with better treatment persistence compared with insulin glargine 100 U/mL or insulin detemir in people with T2D.
The treatment persistence and hospitalisation retrospective analysis identified 181,263 people with T2D, newly treated with insulin in 2016-2017. The study used prescription claims data from the Système National des Données de Santé, a French administrative healthcare database.3
Persistence was defined as remaining on any basal insulin or on the same insulin without discontinuation from the index date to the last prescription. A therapy was deemed discontinued when it was interrupted for a period of 6 months.3

Treatment persistence with basal insulin in adults with T2D

<h3>Hospitalisation3</h3>
Overall, a low number of episodes of hospitalised hypoglycaemia‡&nbsp;were observed in this study regardless of treatment.
The treatment persistence and hospitalisation retrospective analysis identified 181,263&nbsp;people with T2D, newly treated with insulin in 2016-2017. The study used prescription claims data from the Système National des Données de Santé, a French administrative healthcare database.3
Persistence was defined as remaining on any basal insulin or on the same insulin without discontinuation from the index date to the last prescription. A therapy was deemed discontinued when it was interrupted for a period of 6 months.3&nbsp;
‡Hospitalisations for severe hypoglycaemia and associated diagnoses were identified with ICD 10 codes.3

Hospitalisation rates with basal insulin in adults with T2D

<h3>Addition of Toujeo® to GLP-1 RA was associated with significantly improved glycaemic control.9</h3>
DELIVER-G real-world retrospective analysis.
A real-world retrospective analysis in insulin-naïve adults with T2D inadequately controlled on GLP‑1 RA with or without oral antidiabetic drugs (N=271).9
DELIVER-G was a retrospective analysis of 271 people with Type 2 diabetes receiving GLP‑1 RA therapy who were insulin‑naive prior to subsequent treatment intensification with Toujeo® (insulin glargine 300 U/mL). DELIVER‑G analysed data from a large US electronic medical record data source (IBM® Explorys).9

Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

<h3>Toujeo® versus degludec 100 U/mL in people with T1DM8</h3>
One Care study8
The first real-world study to compare 2nd-generation basal insulin analogues, Toujeo® and degludec 100 U/mL, in people with T1DM, using continuous glucose monitoring.8
The primary endpoint of the One Care study was effectiveness of Toujeo® versus insulin degludec 100 U/mL in terms of percentage of time in the predetermined glucose range (70-180 mg/dL). Time in range over the course of a full day was similar in both groups (52.4% for those receiving Toujeo® versus 49.3% for the insulin degludec group. At night the time in range was significantly higher in the Toujeo® group (52.4% versus 46.2%, p=0.0209).8
One Care was an observational, retrospective cohort, cross‑sectional, multicentre study of continuous glucose monitoring data in 199 adults with T1DM in Spain comparing the effectiveness (using percentage of time‑in‑range 70‑180 mg/dL over 14 consecutive days within a 4‑week period) and safety of Toujeo® (insulin glargine 300 units/mL) versus degludec using continuous glucose monitoring in routine clinical practice.8

Limitations of the One Care study:8
<ul>
 <li>No randomisation</li>
 <li>No centralised laboratory</li>
 <li>No intensive control and monitoring of clinical practice</li>
 <li>The degludec 100 U/mL group presented a more severe course of disease (higher rates of retinopathy) compared with the Toujeo® group</li>
</ul>

TYPE-1-DIABETES

Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM

Prescribing Information for SARCLISA®▼&nbsp;(isatuximab) can be found via the Product Card at the bottom of the page.
<h2>In this video, you'll learn about</h2>
A case study presented by Dr Sarah Lawless of an 81 year old RRMM patient who receives SARCLISA® + Pd at 4th Line. The case study demonstrates that elderly patients can tolerate triplet-based therapy and that egh Isa Pd should be considered for all eligible patients at 4th line.

MULTIPLE-MYELOMA

ONCOLOGY

A Real World Case Study:

Presented by Dr Sarah Lawless

<h2>Learn more about SARCLISA®</h2>

Find out more about SARCLISA&reg;&nbsp;+ Pd efficacy and safety data and dosing information.

Download a handy guide to SARCLISA dosing and administration information

Download SARCLISA&reg;&nbsp;patient information.

Get in touch with 
 
 the Oncology Team

<h2 style="text-align: center;">Relapsed Refractory 
 Multiple Myeloma Product</h2>

<a href="http://pro.campus.sanofi/uk/products/sarclisa">Learn more&nbsp; →</a>

<a href="${link:{uuid:{5dabc6e6-c2fb-4d0b-a7a7-fe7742c3375f},repository:{dam},path:{/Portal/UK/Products/sarclisa/Sarclisa-PI-GB-May-2024_campus.pdf}}}">Prescribing information UK</a>

MAT-XU-2202578 (v5.0) 
 Date of preparation: January 2025
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

SARCLISA®▼ (isatuximab) Prescribing Information UK

Prescribing Information for SARCLISA®▼&nbsp;(isatuximab) can be found via the Product Card at the bottom of the page.
<h2>In this video, you'll learn about</h2>
A case study presented by Christine Skeet of an 84 year old RRMM patient who receives SARCLISA® + Pd at 4th Line. The case study examines the practical considerations of managing an elderly patient with lytic bone disease and renal impairment.

A Real World Case Study:

Presented by Christine Skeet

Get in touch with
 
 the Oncology Team

<a href="${link:{uuid:{8a5c89c0-cf01-4337-9360-97b781b40992},repository:{products},path:{/UK/sarclisa}}}">Learn more&nbsp;&nbsp;→</a>

Sanofi is working to harness this modern technology to strengthen understanding and diagnostic outcomes for those living with a rare disease.

BETTER-CARE-FOR-RARE

RARE-DISEASE

Adopting big data & artificial intelligence to
advance diagnosis for rare diseases

Listen to Lucy McKay, CEO of Medics4Rare and Silvia Cerolini, Head of Innovation Specialty Care, Sanofi discuss the benefits of artificial intelligence (AI) and big data in the field of rare disease: “Tools like AI can search for cases, […], who might have a rare condition, in a way that without academic and personal experience, a doctor’s not going to be able to do for all of these rare conditions.” Lucy McKay
This recording is organised and funded by Sanofi.

<h2>In conversation with Lucy McKay, CEO of Medics4RareDiseases &amp; Silvia Cerolini, Head of Innovation Specialty Care, Sanofi</h2>

To explore the diagnostic odyssey further, Dr Lucy McKay and Silvia Cerolini take a deeper dive into this potentially life-changing technology, including the benefits and possible challenges that come with the use of big data and AI in the rare disease arena.
This recording is organised and funded by Sanofi.

Sanofi is working to harness this modern technology to strengthen understanding and diagnostic outcomes for those living with a rare disease.

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local or a QfitliaTM representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles

Multiple Sclerosis

Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D

Treatment persistence with basal insulin in adults with T2D

Hospitalisation rates with basal insulin in adults with T2D

Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA

Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM

A Real World Case Study: Presented by Dr Sarah Lawless

A Real World Case Study: Presented by Christine Skeet

Adopting big data & artificial intelligence to advance diagnosis for rare diseases